- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02566655
Clinical Trial of Intravenous Infusion of Fucosylated Bone Marrow Mesenchyme Cells in Patients With Osteoporosis (CSM/OP/2011)
Phase I Clinical Trial To Evaluate The Intravenous Infusion Of Autologous Fucosylated Bone Marrow Mesenchymal Cells Therapy In Patients With Established Osteoporosis and Low Impact Fractures
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Murcia
-
El Palmar, Murcia, Spain, 30120
- Hospital Clínico Virgen de la Arrixaca
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with established osteoporosis according to standard clinical criteria.
- Patients who give their written informed consent to participate in the study consent.
- Meet all the inclusion criteria
Exclusion Criteria:
- Patients with concomitant systemic disease in the opinion of the investigator.
- Patients with rheumatoid arthritis, ankylosing spondylitis, chronic polyarticular arthritis.
- Current patients with neoplasm or history of any malignancy in the last 10 years except basal carcinoma or epidermoid skin.
- Patients with genetic disorders that are associated with secondary osteoporosis: Hemochromatosis, hypophosphatasia, osteogenesis imperfecta, Ehlers-Danlos syndrome, Marfan syndrome, Riley Day, porphyria, storage diseases syndrome.
- Patients receiving immunosuppressive chemotherapy or that could interfere with the process of cell proliferation.
- Transplant patients: bone marrow, kidney, liver, heart, lung.
- Patients with clinical criteria and anesthetics that contraindicate well sedation or bone marrow extraction.
- Patients participating in a clinical trial in the last 6 months.
- Patients with positive serology for hepatitis B, hepatitis C or HIV.
- Patients with inability to understand informed consent.
- Patients who are pregnant or breast-feeding actively.
- Patients physically fertile, defined as all women physiologically capable of becoming pregnant, UNLESS they are using reliable methods of contraception.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Fucosylated MSC for Osteoporosis
Autologous Bone Marrow fucosylated mesenchymal stem cells will be infused intravenously on Day 0. The first four patients enrolled will receive a single dose of 2 million cells/Kg and the last six patients enrolled, will receive a single dose of 5 million cells/kg.
|
Aproximately 30 days before the infusion of the investigational product, patient bone marrow will be obtained according to standard practice of the Haematology University Hospital Virgen de la Arrixaca (HCUVA). Mononuclear bone marrow cells will be separated and cultured in GMP conditions to purify and obtain mesenchymal cell established dose range. The infusion day BM-MSCs will be fucosylated and resuspended in saline to a concentration of 5 million cells per 1 mL. Then, the final product will be packaged in syringes for intravenous administration to patients through a peripheral venous access. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of serious and non-serious adverse events related to the procedure.
Time Frame: 24 months from baseline
|
During time frame the following items will be considered: Adverse effects related to the infusion moment. Occurrence of infectious complications after infusion of mesenchymal stem cells, because of the immunosuppressive effect of these cells. Appearance of procedure-related neoplasias. |
24 months from baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of new fractures
Time Frame: 24 months from baseline
|
24 months from baseline
|
|
Pain, measured by Visual Analog Scale
Time Frame: 24 months from baseline
|
To measure pain, visual analogue scale (VAS) was used where 0 is no pain and 10 the worst pain imaginable.
|
24 months from baseline
|
Functionality, measured by Oswestry Disability Questionnaire
Time Frame: 24 months from baseline
|
To identify the functional repercussion of lumbar pain, Oswestry Disability Questionnaire for back pain or Oswestry Disability Index is used.
|
24 months from baseline
|
Quality of Life, measured by EuroQoL-5D test
Time Frame: 24 months from baseline
|
To measure the quality of life EuroQoL-5D psychometric test is used.
|
24 months from baseline
|
Bone resorption, measured by biochemical index
Time Frame: 24 months from baseline
|
Aminoterminal telopeptide of type 1 collagen in the serum (serum NTX) (%) by ELISA technique.
|
24 months from baseline
|
Bone formation, measured by biochemical index
Time Frame: 24 months from baseline
|
Osteocalcin in the serum by ELISA (BPG serum) (ng / mL) .
|
24 months from baseline
|
Bone formation, measured by biochemical index
Time Frame: 24 months from baseline
|
Bone specific alkaline phosphatase in the serum by ELISA (serum FAO) (ug / L)
|
24 months from baseline
|
Bone formation, measured by biochemical index
Time Frame: 24 months from baseline
|
Aminoterminal propeptide of procollagen type 1 in the serum by ELISA (serum P1NP) (ng / mL)
|
24 months from baseline
|
Bone metabolism, measured by biochemical index
Time Frame: 24 months from baseline
|
Osteoprotegerin (OPG) (pmol / L) in the serum by ELISA.
|
24 months from baseline
|
Bone metabolism, measured by biochemical index
Time Frame: 24 months from baseline
|
Ligand receptor activator of nuclear factor KB (RANKL) (pmol / L) in the serum by ELISA.
|
24 months from baseline
|
Bone Mineral Density , measured by dual energy x-ray absorptiometry (DXA)
Time Frame: 24 months from baseline
|
24 months from baseline
|
|
Bone structure, measured by histomorphometric evaluation
Time Frame: baseline and 4 months from baseline
|
baseline and 4 months from baseline
|
|
Trabecular bone density measured by quantitative computed tomography of the radius
Time Frame: 24 months from baseline
|
24 months from baseline
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Luis F Linares Ferrando, MD, Hospital Universitario Virgen de la Arrixaca
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CSM/OP/2011
- 2012-005814-20 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoporosis
-
Radius Health, Inc.CompletedOsteoporosis | Osteoporosis Risk | Osteoporosis, Postmenopausal | Osteoporosis Fracture | Osteoporosis, Age-Related | Osteoporosis Localized to Spine | Osteoporosis Senile | Osteoporosis of Vertebrae | Osteoporosis VertebralUnited States
-
Radius Health, Inc.CompletedOsteoporosis | Age Related Osteoporosis | Osteoporosis, Age-Related | Osteoporosis Localized to Spine | Osteoporosis Senile | Osteoporosis of VertebraeUnited States, Poland, Italy
-
Hoffmann-La RocheCompletedPostmenopausal OsteoporosisUnited States
-
Hoffmann-La RocheCompletedPost Menopausal OsteoporosisUnited States, Puerto Rico
-
Centre Hospitalier Universitaire de Saint EtienneMinistry of Health, FranceRecruitingPost Menopausal OsteoporosisFrance
-
AmgenCompletedPost Menopausal OsteoporosisFrance
-
Hoffmann-La RocheCompletedPost Menopausal OsteoporosisUnited States
-
Hoffmann-La RocheCompletedPost Menopausal OsteoporosisSpain, South Africa, Germany, Mexico, United States, Canada, France, United Kingdom, Italy, Belgium, Australia, Poland, Denmark, Hungary, Czech Republic, Norway
-
Hoffmann-La RocheGlaxoSmithKlineCompletedPost Menopausal OsteoporosisFrance
-
Novartis PharmaceuticalsCompletedPost-menopausal OsteoporosisColombia, Belgium, Sweden, Hong Kong, United States, Hungary, Switzerland, Australia, Germany, Italy, Canada, Poland, Argentina, Thailand, Norway, New Zealand, France, Finland
Clinical Trials on Fucosylated MSC for Osteoporosis
-
Red de Terapia CelularFundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia and other collaboratorsUnknown
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...UnknownSystemic Lupus ErythematosusChina
-
Ankara Yildirim Beyazıt UniversityCompletedOsteoporosis | Healthy Lifestyle | University StudentsTurkey
-
R.P.HerrmannThe Alfred; The Queen Elizabeth Hospital; Concord Hospital; Sir Charles Gairdner...Completed
-
Dermama Bioteknologi LaboratoriumKementerian Riset dan Teknologi / Badan Riset dan Inovasi Nasional, IndonesiaRecruitingSARS-CoV2 InfectionIndonesia
-
Loyola Marymount UniversityNational Cancer Institute (NCI)RecruitingLung CancerUnited States
-
Universidad de los Andes, ChileRecruitingLupus Erythematosus, Systemic | Lupus GlomerulonephritisChile
-
Andalusian Initiative for Advanced Therapies -...Andalusian Initiative for Advanced TherapiesCompletedAcute Graft Versus Host DiseaseSpain
-
Asian Institute of Gastroenterology, IndiaCompletedCirrhosis, LiverIndia